Recent advances in multiple myeloma: a Korean perspective

Area of Science:

• Hematology
• Oncology
• Epidemiology

Background:

• Multiple myeloma (MM) incidence is traditionally higher in Western populations compared to Asians.
• Recent data indicate a rising age-standardized incidence rate (ASR) of MM in Asian countries, notably Korea.
• An aging population in Korea is projected to further increase MM incidence.

Purpose of the Study:

• To review the epidemiological trends of multiple myeloma in Korea.
• To discuss advancements in MM diagnosis and treatment.
• To highlight the future medical and socioeconomic impact of MM in Korea.

Main Methods:

• Review of epidemiological data on MM incidence.
• Analysis of recent therapeutic advancements, including novel agents.
• Examination of updated diagnostic and staging criteria for MM.

Main Results:

• The age-standardized incidence rate (ASR) of MM is increasing in Korea.
• Novel agents like carfilzomib, ixazomib, elotuzumab, and daratumumab have improved MM outcomes.
• Modified diagnostic criteria (2014) enhance risk stratification and treatment strategies for smoldering MM.

Conclusions:

• Multiple myeloma represents a growing public health challenge in Korea due to increasing incidence and an aging population.
• Ongoing therapeutic and diagnostic advancements are crucial for managing MM.
• MM will have significant medical and socioeconomic implications in Korea.